Trials / Completed
CompletedNCT01548807
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 dose escalation study of an investigational agent, everolimus, given in combination with standard radiation therapy, in prostate cancers with a rising PSA following a prostatectomy. A maximum of 33 people will be enrolled on this study at the University of Pennsylvania. The primary objective of this study is to determine the acute and chronic toxicities and maximum tolerated dose of everolimus with concurrent radiation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus (RAD001) |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2017-01-04
- Completion
- 2017-01-04
- First posted
- 2012-03-08
- Last updated
- 2018-08-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01548807. Inclusion in this directory is not an endorsement.